

AN 1992-358761 [44] WPIX

DNC C1992-159248

TI Use of new and known phenyl-sulphonyl-amino-pyrimidine derivs. - as endothelin antagonists for treating hypertonia, ischaemia, vasospasm, angina pectoris, etc..

DC B03

IN BURRI, K; CLOZEL, M; FISCHLI, W; HIRTH, G; LOFFLER, B M; RAMUZ, H; LOEFFLER, B M; BURRL, K; FISCHLL, W

PA (HOFF) HOFFMANN LA ROCHE & CO AG F; (HOFF) HOFFMANN LA ROCHE AG; (HOFF) HOFFMANN LA ROCHE INC

CYC 31

PI EP 510526 A1 19921028 (199244)* GE 37<--

R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

AU 9214976 A 19921029 (199251)

NO 9201609 A 19921026 (199252)

CA 2067288 A 19921026 (199303)

FI 9201850 A 19921026 (199304)

HU 61289 T 19921230 (199306)

ZA 9202832 A 19930127 (199310) 73

JP 05155864 A 19930622 (199329) 34

US 5270313 A 19931214 (199350) 22

JP 06070021 B2 19940907 (199434) 34

AU 652238 B 19940818 (199435)

NZ 242396 A 19941222 (199505)

TW 270116 A 19960211 (199621)

IL 101650 A 19961016 (199648)

EP 510526 B1 19961204 (199702) GE 38<--

R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

DE 59207601 G 19970116 (199708)

ES 2096673 T3 19970316 (199718)

NO 300874 B1 19970811 (199739)

RU 2083567 C1 19970710 (199809) 25

PH 29406 A 19960115 (199907)

KR 238366 B1 20000201 (200118)

IE 81631 B 20010321 (200119)

ADT EP 510526 A1 EP 1992-106602 19920416; AU 9214976 A AU 1992-14976 19920416;

NO 9201609 A NO 1992-1609 19920424; CA 2067288 A CA 1992-2067288 19920427;

FI 9201850 A FI 1992-1850 19920424; HU 61289 T HU 1992-1329 19920421; ZA

9202832 A ZA 1992-2832 19920416; JP 05155864 A JP 1992-126708 19920421; US

5270313 A US 1992-869274 19920415; JP 06070021 B2 JP 1992-126708 19920421;

AU 652238 B AU 1992-14976 19920416; NZ 242396 A NZ 1992-242396 19920416;

TW 270116 A TW 1992-102725 19920409; IL 101650 A IL 1992-101650 19920420;

EP 510526 B1 EP 1992-106602 19920416; DE 59207601 G DE 1992-507601

19920416; EP 1992-106602 19920416; ES 2096673 T3 EP 1992-106602 19920416;

NO 300874 B1 NO 1992-1609 19920424; RU 2083567 C1 SU 1992-5011295

19920131; PH 29406 A PH 1992-44258 19920424; KR 238366 B1 KR 1992-7084

19920424; IE 81631 B IE 1992-1341 19920424

FDT JP 06070021 B2 Based on JP 05155864; AU 652238 B Previous Publ. AU

9214976; DE 59207601 G Based on EP 510526; ES 2096673 T3 Based on EP

510526; NO 300874 B1 Previous Publ. NO 9201609

PRAI CH 1991-1242 19910425; CH 1992-343 19920206

AN 1992-358761 [44] WPIX

AB EP 510526 A UPAB: 19931116

Use of phenylsulphonylamino-pyrimidine derivs. of formula (I), or salts of (I), as active agents in the preparation of medicaments for treatment of circulation disorders, especially hypertension, ischaemia, vasospasms and angina pectoris, is new. In (I), R1= H, lower alkyl, lower alkoxy, lower alkylthio, halo or CF3; R2= H, halo, CF3, lower alkoxy or hydroxy-lower alkoxy; R3= H, OH, halo, alkylthio, cycloalkyl, hydroxy-lower alkyl, hydroxy-lower alkyl,

hydroxyimine lower alkyl, lower alkenyl, oxo-lower-alkyl, CF₃, CF₃O, lower alkoxy, lower alkoxy-lower alkoxy or aryl-lower alkoxy; or R₂+R₃= butadienyl; R₄= H, lower alkyl, aryl or heteroaryl; R₅= H, lower alkanoyl, benzoyl, heterocyclyl-carbonyl or tetrahydropyran-2-yl; R₆= a gp. of formula (i) or (ii) (where R₇= H, NO₂ or lower alkoxy; R₈= H, halo, lower alkyl, lower alkoxy, lower alkylthio, NO₂, OH, NH₂ or CF₃; or R₇+R₈= butadienyl; R₉= H, halo, CF₃, lower alkyl, lower alkoxy or lower alkylthio; R₁₀= H, halo, lower alkyl, lower alkoxy or lower alkylthio); X, Y= O, S or NH; n= 2, 3 or 4.

(I) are new; (a) when R₆ is a gp. of formula (ii), R₉ is halo, lower alkoxy, lower alkylthio or CF₃, and R₁₀ is H or lower alkoxy, and (b) when R₆ is a gp. of formula (i) and R₈ is not OH, NH₂ or CF₃.

USE - (I) are endothelin antagonists and are useful in treatment of, e.g. hypertension, coronary insufficiency, renal insufficiency, ischaemia, cerebral infarct, migraine, atherosclerosis, gastric and duodenal ulcers, inflammation, shock, glomerulonephritis, renal colic, glaucoma, asthma and in treatment and prophylaxis of diabetic complications and complications resulting from admin. of cyclosporins. Known (I) (see DE1545944) are useful in reducing blood pressure. Admin. is oral, rectal or parenteral, in doses of 0.1-100 mg/kg/day Dwg.0/0

ABEQ US 5270313 A UPAB: 19940203

Sulphonamide derivs. of formula (I) and their salts are new; R₁ is H, lower alkyl, lower alkoxy, lower alkylthio, halo or CF₃; R₂ is H, halo, lower alkoxy, hydroxy-lower alkoxy or CF₃; R₃ is H, OH, halo, alkylthio, cycloalkyl, lower alkyl, hydroxy-lower alkyl, hydroxy-lower alkoxy, hydroximino-lower alkyl, lower alkenyl, oxo-lower alkyl, CF₃, OCF₃, lower alkoxy, lower alkoxy-lower alkoxy or aryl-lower alkoxy; aryl is phenyl opt. substd. by halo, lower alkyl or lower alkoxy; or R₂ with R₃ form butadienyl; R₄ is H, lower alkyl, phenyl opt. substd. by halo, lower alkyl or lower alkoxy, pyrimidinyl, pyridyl, pyrazinyl, pyridazinyl and thienyl; R₅ is H, lower alkanoyl, benzoyl, 2-pyridylcarbonyl, 3-pyridylcarbonyl, 4-pyridylcarbonyl, 3-methylisoxazol-5-yl-carbonyl, 2-furoyl, 3-furoyl, 2-thenoyl, 3-thenoyl or tetrahydropyran-2-yl; R₆ is a gp. of formula (i); R₁₁ is halo, lower alkoxy, lower alkylthio or CF₃; R₁₂ is H or lower alkoxy; X and Y are independently O, S or NH; n is 2, 3 or 4. Use of (I) to treat circulatory disorders is claimed where R₅ may also be a gp. (ii) in which R₇ is H, lower alkoxy or nitro; R₈ is H, halo, lower alkyl, lower alkoxy, lower alkyl; thio, nitro, OH, amino or CF₃; or R₇ with R₈ form butadienyl; R₉ is H, halo, lower alkyl, lower alkoxy, lower alkylthio or CF₃; R₁₀ is H, halo, lower alkyl, lower alkoxy or lower alkylthio. USE/ADVANTAGE - (I) are used to treat esp. hypertension, ischemia, vasospasms and angina pectoris.

Dwg.0/0

ABEQ EP 510526 B UPAB: 19970108

The use of compounds of the formula (I); wherein R₁ signifies hydrogen, lower-alkyl, lower-alkoxy, lower-alkylthio, halogen or trifluoromethyl, R₂ signifies hydrogen, halogen, lower-alkoxy, hydroxy-lower-alkoxy or trifluoromethyl; and R₃ signifies hydrogen, hydroxy, halogen, alkylthio, cycloalkyl, hydroxy-lower-alkyl, hydroxy-lower-alkoxy, hydroximino-lower-alkyl lower-alkenyl, oxo-lower-alkyl, trifluoromethyl, trifluoromethoxy, lower-alkoxy, lower-alkoxy-lower-alkoxy or aryl-lower-alkoxy; R₂ and R₃ together signify butadienyl; R₄ signifies hydrogen, lower-alkyl aryl or heteroaryl, R₅ signifies hydrogen, lower-alkanoyl, benzoyl, heterocyclyl-carbonyl or tetrahydropyran-2-yl; R₆ signifies a residue of the formula (a)-(b); R₇ signifies hydrogen, lower-alkoxy or nitro; and R₈ signifies hydrogen, halogen, lower-alkyl, lower-alkoxy, lower-alkylthio, nitro, hydroxy, amino, or trifluoromethyl; R₇ and R₈ together signify butadienyl; R₉ signifies hydrogen, halogen, lower-alkyl, lower-alkoxy, lower-alkylthio or trifluoromethyl; R₁₀ signifies hydrogen, halogen, lower-alkyl lower-alkoxy or lower-alkylthio; X and Y each independently signify O, S or NH; and n signifies 2, 3, or 4; whereby "lower" denotes residues with 1-7C atoms; and salts thereof as active ingredients for the manufacture of medicaments for the treatment of circulatory disorders, especially hypertension, ischemia, vasospasms and angina pectoris. Dwg.0/0